100053-8Fluoroquinolone [Susceptibility]Active
Part Description
LP266717-0 Fluoroquinolone
Fluorquinolones are among most beneficial drugs used to treat multi-drug resistant Mycobacterium tuberculosis (MDR-TB) infections. The fluorquinolones affect the activity of DNA gyrase by reducing the cell's ability for DNA replication and transcription. DNA gyrase in Mycobacterium tuberculosis (TB) is made of two subunits that are encoded by gyrA and gyrB. Mutations in the gyrA quinolone resistance-determining region (QRDR) are responsible for causing most of the drug resistance of TB to the fluoroquinolones. The gyrB mutations have a much smaller impact on TB resistance to the fluoroquinolones.[PMID:26763957]
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Fluoroquinolone
- Property
- Susc
- Time
- Pt
- System
- Isolate
- Scale
- OrdQn
- Method
Additional Names
- Short Name
- FLQ Susc Islt
- Display Name
- Fluoroquinolone [Susc]
- Consumer Name Alpha
- Susceptibility to Fluoroquinolone
Example Answer List LL360-9
Source: Regenstrief Institute
| Answer | Code | Score | Answer ID |
|---|---|---|---|
| Positive Copyright http://snomed.info/sct ID:10828004 Positive (qualifier value) | LA6576-8 | ||
| Negative Copyright http://snomed.info/sct ID:260385009 Negative (qualifier value) | LA6577-6 |
Basic Attributes
- Class
- ABXBACT
- Type
- Laboratory
- First Released
- Version 2.72
- Last Updated
- Version 2.72
- Order vs. Observation
- Both
Member of these Groups
| LG51364-4 | FluoroquinoloneSusc| |
Language Variants Get Info
- zh-CNChinese (China)
- 氟喹诺酮:
抗生素敏感性: 时间点: 分离株: 定量型或序数型: - nl-NLDutch (Netherlands)
- fluorchinolon:
gevoeligheid: moment: isolaat: ordinaal-kwantitatief: - it-ITItalian (Italy)
- Fluorochinolone:
Susc: Pt: Isolato: OrdQn: - es-ESSpanish (Spain)
- Fluoroquinolona:
Susceptibilidad: Punto temporal: Aislado: Ordinal Cuantitativo:
LOINC FHIR® API Example - CodeSystem Request Get Info
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=100053-8
Third Party Copyright
This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.
This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.
Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.
LOINC Copyright
Copyright © 2022 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright